-
ABOUT USAffiliated to SSY Group Limited, Hebei Guangxiang Technology Co., Ltd., is a high-tech enterprise specializing in drug research and technology development.
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the synergy between “industry, academia, research and application” based on multi-disciplinary integration and multi-directional combination.
-
SUBORDINATEThe group has decided to establish research institutes in its subsidiaries, Hebei Ghuangxiang Drug Research Institute, Jiangsu Best Medical Material Research Institute, and Hebei Hanlin Biological Research Institute.
-
RECRUITWe actively establish a joint talent cultivation mechanism between schools and enterprises, and currently have over 500 high-level talents in various fields such as drug research, analysis, and clinical practice.
-
CONTACTWe will continue to strengthen innovation-driven development, vigorously promote the integration of production and research, constantly improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs.
[Promoting Entrepreneurial Spirit—Interview with a Well-Known Entrepreneur from Hebei] Firmly Upholding Confidence in Enterprise Development and Contributing to the Building of a Healthy China—An Interview with Su Xuejun, Chairman of Shijiazhuang Sihua Pharmaceutical Co., Ltd.
Category:
Time：2020-07-25
“General Secretary Xi Jinping’s important speech has given market entities and entrepreneurs even greater confidence and enabled them to focus wholeheartedly on development.” General Secretary Xi Jinping’s important speech delivered at the symposium for entrepreneurs on July 21 sparked a warm response at Shijiazhuang Sihua Pharmaceutical Co., Ltd. Su Xuejun, Chairman of Shijiazhuang Sihua Pharmaceutical, stated that they will uphold the entrepreneurial spirit in accordance with the General Secretary’s requirements.
“General Secretary Xi Jinping’s important speech has further bolstered the confidence of market entities and entrepreneurs, encouraging them to focus wholeheartedly on development.” General Secretary Xi Jinping’s important speech delivered at the symposium for entrepreneurs on July 21 has elicited a warm response at Shijiazhuang No.4 Pharmaceutical Co., Ltd. Su Xuejun, Chairman of Shijiazhuang No.4 Pharmaceutical, stated that, in accordance with the General Secretary’s instructions, they must carry forward the entrepreneurial spirit and continuously enhance their commitment to patriotism, innovation, integrity, social responsibility, and global vision. They should more consciously align the future and destiny of their enterprises with those of the nation, shoulder the responsibility for the country’s prosperity and the rejuvenation of the Chinese nation, and strive to contribute to the building of a Healthy China.
Su Xuejun, Chairman of Shijiazhuang Fourth Pharmaceutical
Innovation never stops—igniting high-quality momentum.
Shijiazhuang Fourth Pharmaceutical is a large-scale pharmaceutical enterprise in our province, primarily engaged in the production of chemical drugs, active pharmaceutical ingredients, and pharmaceutical packaging materials. It is a leading Chinese company in the production, R&D, and export of intravenous solutions. In the China Top 100 Pharmaceutical Companies list released on July 22, Shijiazhuang Fourth Pharmaceutical once again made the “Top 100 Chinese Chemical Pharmaceutical Enterprises” ranking, placing 45th.
“In recent years, Shijiazhuang No.4 Pharmaceutical has made significant strides in both its business scale and corporate profitability. An important factor behind this progress is that we’ve firmly grasped the ‘crucial lever’ of innovation and continuously drawn momentum from innovative development,” said Su Xuejun, Chairman of Shijiazhuang No.4 Pharmaceutical. He added that unwavering commitment to innovation is a key component of promoting the entrepreneurial spirit in the new era—a vital approach for strengthening and solidifying the foundation of our enterprise.
“Over the past few years, we’ve invested more than 5% of our sales revenue in innovation, successfully establishing high-level research and innovation platforms such as the National Enterprise Technology Center, the National-Local Joint Engineering Laboratory, and the Postdoctoral Research Workstation. We’ve also partnered with renowned universities including Zhejiang University, Tianjin University, and Zhengzhou University to co-build research centers, thereby creating a comprehensive, scientific, and well-defined technological innovation system. As a result, our technological innovation capabilities and levels have steadily begun to align with those of the ‘national team’,” said Su Xuejun. He emphasized that adhering to an innovation-driven strategy is the very foundation for the company’s growth and development.
Innovation is the primary driving force behind development. As a national high-tech enterprise, Shijiazhuang Sihua Pharmaceutical places great importance on technological R&D and investment in human capital, effectively harnessing the creativity of its employees and striving to build the company into a powerful innovation leader. Currently, the Pharmaceutical Research Institute of Shijiazhuang Sihua Pharmaceutical Co., Ltd. boasts nearly 500 highly qualified professionals specializing in drug research, analysis, clinical studies, and other advanced fields. The institute has established a relatively comprehensive scientific research and innovation system among domestic pharmaceutical companies, attracting numerous top-tier talents—including doctors and experts—who lead innovative teams and are undertaking several major national and provincial science and technology innovation and industrialization projects.
Innovation requires courage, but it also entails risks and challenges. With the boldness and determination to face any challenge head-on, Shijiazhuang Fourth Pharmaceutical has, after years of arduous efforts, reached a glorious moment of remarkable breakthroughs built on a solid foundation of accumulated strength. Currently, Shijiazhuang Fourth Pharmaceutical launches more than 10 new products each year and has secured over 80 core, independently owned intellectual property rights. The company is also developing more than 160 pipeline products, including several first-in-class novel drugs. “As General Secretary Xi Jinping has pointed out, daring to take the lead is precisely the quality that we must vigorously promote in order to overcome risks and challenges and achieve high-quality development,” said Su Xuejun.
Shijiazhuang Fourth Pharmaceutical Modernized Factory Area
Only through hard work can we truly savor the joy that comes with achieving our goals. The range of new products—represented by injection solutions—is steadily expanding. Since last year, we have obtained a total of 18 approval certificates for generic drug production and 2 certificates for consistency evaluations. Among these, the sodium chloride injection containing tirofiban hydrochloride, a cardiovascular medication, is currently being clinically used to treat acute coronary syndrome. It’s a therapeutic agent with tremendous clinical potential and will become a flagship product supporting the company’s growth in the injection solution segment. The newly approved series of peritoneal dialysis solutions, when combined with our existing peritoneal dialysis products, will help the company enter the dialysis market and continuously expand its growth prospects. The hydroxyethyl starch 130 sodium chloride injection is poised to carve out a niche for itself in the blood volume and anesthesia markets. The three specifications of ambroxol ampoule injections will further enrich our respiratory product line. Moreover, the fluconazole tablets in both 50mg and 150mg dosages have passed the consistency evaluation; notably, the 150mg dosage is the first of its kind in China to receive such approval, and it is expected to demonstrate strong market potential in future national bidding processes. Su Xuejun spoke about these research achievements with great enthusiasm and detailed knowledge.
Building enterprises on trust, solidifying the foundation for development.
“Socialist market economy is an economy based on credit and the rule of law,” General Secretary Xi Jinping succinctly summarized the key characteristics of the socialist market economy at the symposium for entrepreneurs.
“Without trust, no one can stand firm—and this is especially true for enterprises and entrepreneurs. To promote the entrepreneurial spirit, we must firmly uphold the rule of law, embrace the spirit of contract, and adhere to the principle of honoring our commitments. Only then can we bravely take the lead in the tide of the market economy and remain invincible,” said Su Xuejun, who deeply appreciates the impact of the credit economy on enterprise development.
Su Xuejun said that Shijiazhuang No.4 Pharmaceutical builds its business on trust, regarding integrity as the intangible strength driving its corporate development and establishing “integrity first” as the company’s core spirit, thereby consciously regulating contractual behavior. Adhering to a “high-quality strategy,” the company has earned one prestigious corporate honor after another—such as the “Hebei Provincial Government Quality Award,” “AAA Credit Enterprise of China,” “National Contract-Abiding and Creditworthy Enterprise,” and “Hebei Province Integrity Enterprise”—by delivering high-quality products and services.
Excellent corporate credit has enabled Shijiazhuang Fourth Pharmaceutical to enjoy smooth sailing in overseas markets, establishing a “golden brand” in the eyes of international customers. To date, Shijiazhuang Fourth Pharmaceutical has obtained nearly 30 international certifications and undergone quality audits in multiple countries, with cumulative exports reaching over 90 countries and regions. The company has also registered more than 200 product specifications, including ciprofloxacin lactate sodium chloride injection, metronidazole sodium chloride injection, sodium lactate Ringer’s injection, 18AA amino acid injection, and mannitol injection. In 2019, the company firmly held the leading position among domestic intravenous solution manufacturers in terms of exports, achieving double-digit growth in exports for eight consecutive years.
Shijiazhuang Fourth Pharmaceutical’s world-class research facilities provide strong support and assurance for product development.
At a time when the COVID-19 pandemic is spreading globally, fulfilling contractual obligations on time and stabilizing foreign trade demonstrate the sense of responsibility of a company that acts with integrity. Shijiazhuang Sihua Pharmaceutical has actively responded to the impact of the pandemic while maintaining unwavering focus on foreign trade. By adopting “screen-to-screen” and “line-to-line” communication methods, the company has ensured that orders are fulfilled without delay, new orders keep coming in, and customer service remains uninterrupted, thereby earning the trust of international business partners and boosting confidence in cooperation between both sides. In the first half of this year, foreign trade sales volume and export value have maintained a strong momentum of continuous growth.
Put our original aspirations and mission into practice and sincerely give back to society.
“To carry forward the spirit of entrepreneurship, we must proactively take on national responsibilities, share the nation’s burdens, and fully fulfill our duty to serve the country,” said Su Xuejun.
During the pandemic, Shijiazhuang No.4 Pharmaceutical Company resolutely shouldered its social responsibility in epidemic prevention and control. With a strong sense of mission and commitment, the company mobilized its employees to the fullest extent to ensure the production of key protective medications such as Abidol Hydrochloride Capsules, Moxifloxacin Hydrochloride Sodium Injection, and basic intravenous solutions. Moreover, the company promptly organized and dispatched emergency medicines to support frontline efforts in Hubei Province, contributing the strength of a pharmaceutical enterprise to winning the people’s war, the overall battle, and the decisive battle against the epidemic—thus demonstrating through action the original aspirations and mission of pharmaceutical professionals.
During the pandemic, Shijiazhuang No.4 Pharmaceutical Company worked overtime to produce the antiviral drug Abidor capsules.
During this period, Shijiazhuang No.4 Pharmaceutical Company provided 3.962 million Abidol capsules and 500,000 bags of anti-epidemic drugs such as moxifloxacin hydrochloride sodium injection to Hubei Province. The company also donated cash and materials totaling over 3 million yuan to designated hospitals for COVID-19 treatment in Wuhan and the Shennongjia Forestry District. Additionally, it supplied 410,000 bottles (or buckets) of disinfectant solutions to Beijing and Tianjin. The company successfully completed the national allocation and provincial storage tasks, earning high praise from the Medical Supplies Guarantee Group of the Joint Prevention and Control Mechanism under the State Council for the Novel Coronavirus Pneumonia Epidemic, the Party Committee and government of the Shennongjia Forestry District, the Hubei Provincial Epidemic Command Center, and relevant medical institutions.
“As an important market player in the socialist market economy, private enterprises should share the same fate and breathe together with the nation’s development. We must closely integrate enterprise development with national prosperity, the rejuvenation of the nation, and the happiness of the people, strive for high-quality enterprise growth, and contribute to the building of a Healthy China!” said Su Xuejun.
(Originally published in “
Great Wall Network
》
)
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Mobile site
E code
Business license